Search PubMed⌕ Search

Biomedical subjects

L Kayasseh

Publications and source records attributed to L Kayasseh.

At least 37 records · Page 2Linked to original sources
PubMed1980

[Chemical structure and biological activity of cholecystokizin octapeptides with respect to the stomach and pancreas].

Dose response curves of the octapeptide of cholecystokinin (CCK-8) and 3 of its methoxinine analogues have been established in 4 conscious dogs with respect to gastric and pancreatic secretion. In the analogues the methionine was replaced by methoxinine in position 3 (B) and (D) or 6 (C). Of the 4 tested substances CCK-8 exhibited most activity with regard to pancreatic protein secretion, followed by B, C, and D. Analogue C had the strongest stimulating effect on gastric acid secretion, while its effect on pancreatic secretion was minor. Correlation of chemical structure with biological activity points to the importance of the methionine residue in position 6.

Animals↗
PubMed1980

Somatostatin and cimetidine in peptic-ulcer haemorrhage. A randomised controlled trial.

In a randomised controlled trial somatostatin was compared with cimetidine in the treatment of severe and persistent gastrointestinal bleeding due to peptic ulcer. The study was of a sequential design and lasted 2.5 years, when the designated level of significance had been reached. Of the 20 patients studied, 10 received somotostatin and 10 received cimetidine. In 7 of the 10 pairs of patients somatostatin was more effective than cimetidine; in 2 pairs somatostatin and cimetidine were both ineffective; and in 1 pair they were equally effective. Somatostatin may therefore be suitable for controlling peptic-ulcer bleeding in many patients who are unsuitable for surgery.

Adult↗
PubMed1980

Biological activity of the C-terminal octapeptide of cholecystokinin, of three of its analogues and of caerulein in the dog.

Dose-response curves of the C-terminal octapeptide (CCK-8) of cholecystokinin, of 3 of its methoxinine analogues, and of caerulein for various variables of exocrine pancreatic secretion have been established in conscious dogs. The following relative potencies were calculated for the protein secretion activity of CCK-8 (100%), [Mox3]-CCK-8 (52%), [Mox6]-CCK-8 (27%), [Mox3,Mox6]-CCK-8 (19%) and caerulein (178%).

Animals↗
PubMed1980

[The study of exocrine pancreas function by means of orally administered N-benzoyl-L-tyrosyl-praaminobenzoic acid (BT-PABA-test). Evaluation after 5 years clinical experience].

Exocrine pancreatic function was assessed in 588 persons by oral administration of 1 g of the chymotrypsin-labile peptide N-benzoyl-L-tyrosyl-paraaminobenzoic acid (BT-PABA) from 1974 to 1979. The BT-PABA-test was performed in 126 controls, 217 patients with pancreatic diseases, 196 patients with various non-pancreatic gastrointestinal diseases, 18 patients with renal diseases, and 31 patients with various other diagnoses. In 62 of 72 patients (86.1%) with chronic pancreatitis and in 19 of 25 patients with pancreatic carcinoma the excretion of paraaminobenzoic acid (PABA) in the urine was significantly less than in the controls. In contrast, 328 of 353 controls and patients with non-pancreatic diseases (92.9%) had a PABA excretion within normal limits. The sensitivity and specificity of the BT-PABA observed in this study is sufficient to detect moderate to severe disturbances of exocrine pancreatic function. The replacement of the liquid test-meal by a standard breakfast and additional meals taken during the collection period 4 or 5 hours after peptide intake did not influence the results of the BT-PABA-test, thus considerably simplifying the BT-PABA-test.

4-Aminobenzoic Acid↗
PubMed1980

[Somatostatin and cimetidine in peptic ulcer hemorrhage. A randomized controlled study].

The efficacy of somatostatin in 20 patients with severe and persistent gastrointestinal bleeding due to peptic ulcer was investigated in a randomised controlled trial in comparison with cimetidine. Seven of the 10 pairs of patients showed a result favourable for somatostatin, but no pair showed an outcome in favour of cimetidine. Three pairs were tied: 2 with double failure and 1 with double success.

Cimetidine↗
PubMed1979

Immunological blocking of exogenous and endogenous secretin in the dog.

In mongrel dogs with chronic gastric and duodenal fistula the biological activity of secretin on exocrine pancreatic secretion could be blocked by preincubating the secretin injected with rabbit antisecretin antibody. In addition, the activity of endogenous secretin released by acid was markedly reduced by application of antibody. Since no such effect was observed after testmeal stimulation, secretin is most probably not released in a significant amount by the liquid meal used in this experiment.

Animals↗
PubMed1979

[Dosage dependence of the effect of somatostatin on human splanchnic blood flow].

The effect of three different doses of somatostatin on splanchnic blood flow (SBF) and on arterial plasma insulin, glucagon and glucose was determined. 125, 250 and 500 microgram/h of somatostatin was infused during 60 minutes in 3 groups of 6 patients undergoing arterial-hepatic-venous catheterization; no patient had clinical evidence of metabolitic or hepatic disease. Continuous infusion of 125 microgram/h somatostatin was without significant effect on SBF, whereas 250 microgram/h resulted in a mean 28% reduction of SBF (p less than 0.05). Doubling the dose to 500 microgram/h affected SBF similarly (21% reduction of SBF). In contrast, administration of all three doses of somatostatin suppressed the circulating insulin and glucagon levels significantly. In a recent report somatostatin had been administered in a dose of 250 microgram/h to control gastric ulcer hemorrhage. The present studies demonstrate that this dose results in a significant reduction of SBF which cannot be further depressed by increasing the dose.

Adult↗
PubMed1979

[Caerulein and the test meal: a comparison of their effects on pancreatic exocrine secretion in the dog].

Relatively small doses of caerulein (10, 20, 40, 100 ng/kg/h) were given to conscious dogs with chronic duodenal and gastric fistulas and the exocrine pancreatic response was compared with that obtained by a test meal. Test meal stimulated pancreatic secretion was nearly equivalent to that achieved with 10 ng caerulein/kg/h. Plasma secretin levels did not significantly change during test meal stimulation.

Animal Feed↗
PubMed1979

[Effect of duodenal acidification on plasma secretin and pancreatic polypeptide in man (author's transl)].

Plasma secretin and pancreatic polypeptide has been measured in 10 normal volunteers before and after intraduodenal acidification. Secretin rose rapidly from 1,4 +/- 0,44 to 11,2 +/- 1,24 pmol/l (+/- SEM). PP also rose significantly from 39,0 +/- 3,0 to 52.3 +/- 5,8 pmol (paired p less than 0.01) but much slower and to a lesser extent than seen after a meal. This supports the conclusion that acid plays no important role in control of postprandial PP release.

Adult↗
PubMed1978

[Conservative therapy of acute ulcer hemorrhage using somatostatin. Pilot study].

Somatostatin (SST) infusion was used to treat severe upper intestinal hemorrhage in 10 patients with peptic ulcer disease. Bleeding ceased in all patients 4-8 h after start of infusion. In one case bleeding recurred when SST infusion was discontinued; SST was given again and the hemorrhage definitively halted. Another patient suffered a recurrence while under SST infusion and had to be operated upon. SST appears to be effective in controlling hemorrhage from peptic ulcer, though further studies are required.

Adult↗
PubMed1978

Comparison of the biological potency of a new synthetic preparation of secretin with that of natural porcine secretin in the dog.

The biological activity of the new synthetic secretin, Roche, on exocrine pancreatic secretion was determined in conscious dogs with chronic gastric and duodenal fistulae and compared with that of pure porcine secretin (GIH, Karolinska Institutet, Stockholm). The two secretin preparations were found to be equipotent as to pancreatic volume and bicarbonate response on a molar basis. It was concluded that the new synthetic secretin is useful for clinical and research purposes.

Animals↗
PubMed1978

Effect of somatostatin on exocrine pancreatic secretion stimulated by pancreozymin-secretin or by a test meal in the dog.

In 4 dogs with chronic duodenal and gastric fistulae, exocrine pancreatic function was assessed by cannulating the pancreatic duct and collecting the duodenal contents. Both methods were applied in each animal. Pancreatic secretion was stimulated by infusion of 2 CHR units of pancreozymin and secretin or by administration of a liquid test meal, injected into the stomach through the gastric fistula. During both experiments 3.5 microgram/kg somatostatin was given as bolus injection followed by an infusion of 3.5 microgram/kg/h. Somatostatin caused a significant reduction in protein and amylase output and in the bicarbonate concentration during stimulation with pancreozymin-secretin. Volume and bicarbonate slightly decreased but not to a significant extent. Duodenal volume and the duodenal activities of trypsin and amylase were significantly reduced during test meal stimulation and somatostatin infusion. Somatostatin is a potent inhibitor of exocrine pancreatic function mainly influencing enzyme secretion.

Amylases↗
PubMed1978

The endogenous release of pancreatic polypeptide by acid and meal in dogs. Effect of somatostatin.

The response of pancreatic polypeptide (PP) to testmeal (5 ml/kg) and intraduodenal acid (4 mEq HCl/5min) and its reaction to somatostatin (3.5 microgram/kg/h following bolus injection of 3.5 microgram/kg) was studied in dogs with chronic duodenal and gastric fistulae. In addition the influence of atropin (0.5 mg/kg/h) on acid-induced PP response was examined. PP was measured by radioimmunoassay pancreatic secretion by determinating volume, bicarbonate, protein, and enzyme in duodenal contents and pancreatic juice. Plasma PP increased significantly following intraduodenal application of testmeal and hydrochloric acid. Its release was completely suppressed by SST. Furthermore, PP response to intraduodenal acid was blocked by atropin. Exocrine pancreatic secretion of bicarbonate and protein was inhibited by somatostatin as well as atropin. Since PP was released following administration of testmeal and acid, both potent stimulators of pancreatotropic duodenal hormones, it may play an important role in the control of the entero-pancreatic axis. The effect of atropin indicates a cholinergic nervous component of PP release.

Amylases↗
PubMed1978

[The oral administration of N-benzoyl-L-tyrosyl-paraaminobenzoic acid (PFT) in the assessment of exocrine pancreatic function and its value within the diagnostic approach to pancreatic disease (author's transl)].

Exocrine pancreatic function was determined by the oral administration of N-benzoyl-L-tyrosyl-PABA in 343 persons, including controls, patients with diseases of the pancreas, and patients with non-pancreatic disease. The results revealed a sensitivity of 85% in chronic pancreatitis and of 78% in carcinoma of the pancreas. The specificity of the PFT amounted to 92%. No toxic side effects were noted. The PFT is likely to be a useful screening procedure for pancreatic disease.

4-Aminobenzoic Acid↗